Literature DB >> 15378357

Prognostic value of keratin subtyping in transitional cell carcinoma of the upper urinary tract.

Cord Langner1, Beate J Wegscheider, Peter Rehak, Manfred Ratschek, Richard Zigeuner.   

Abstract

To investigate the prognostic value of keratin subtyping in invasive transitional cell carcinomas (TCCs), we performed a systematic study applying 15 different monoclonal keratin antibodies on 53 upper urinary tract TCCs using a tissue microarray technique. Immunoreactivity was correlated with pT stages and tumour grades using the Fisher's exact test. Impact on disease-free survival was analysed using the Kaplan-Meier method and compared by the log-rank test. Immunoreactivity for keratins 5/6, 6, 7, 8, 13, 14, 17, 18, 19, 20, low molecular weight (LMW) keratins (8, 18) and high molecular weight (HMW) keratins (1, 5, 10, 14) was detected in varying quantities. Regarding semi-quantitative assessment, a prognostic impact was found for keratins 5/6, 7, 8, 13, 17, 20 and HMW keratins, with reduced expression or loss of immunoreactivity being significantly associated with disease progression. With respect to analysis of staining patterns, the retention of a basally accentuated labelling for keratin 5/6 and HMW keratin as well as a superficially accentuated labelling for keratin 20 was significantly associated with a favourable outcome. In conclusion, this investigation is the first to demonstrate a possible prognostic value for keratin subtyping in invasive (upper urinary tract) TCCs with respect to metastasis-free survival. Further studies, however, are needed to substantiate our results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378357     DOI: 10.1007/s00428-004-1088-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  35 in total

1.  Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.

Authors:  P Harnden; N Mahmood; J Southgate
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

2.  Cytokeratin alterations as diagnostic and prognostic markers of oral and pharyngeal carcinomas. A prospective study.

Authors:  J Depondt; A H Shabana; H Sawaf; P Gehanno; N Forest
Journal:  Eur J Oral Sci       Date:  1999-12       Impact factor: 2.612

3.  Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression.

Authors:  H E Schaafsma; F C Ramaekers; G N van Muijen; E B Lane; I M Leigh; H Robben; A Huijsmans; E C Ooms; D J Ruiter
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

4.  Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas.

Authors:  P Harnden; J Southgate
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

5.  Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.

Authors:  P Chu; E Wu; L M Weiss
Journal:  Mod Pathol       Date:  2000-09       Impact factor: 7.842

6.  Immunohistochemical profile of common epithelial neoplasms arising in the kidney.

Authors:  Mi-Kyung Kim; Seonwoo Kim
Journal:  Appl Immunohistochem Mol Morphol       Date:  2002-12

Review 7.  Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review.

Authors:  Elizabeth M Genega; Christopher R Porter
Journal:  Am J Clin Pathol       Date:  2002-06       Impact factor: 2.493

8.  Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease.

Authors:  P Harnden; A Allam; A D Joyce; A Patel; P Selby; J Southgate
Journal:  Histopathology       Date:  1995-08       Impact factor: 5.087

9.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.

Authors:  R Moll; A Löwe; J Laufer; W W Franke
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

10.  Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.

Authors:  Douglas C Parker; Andrew L Folpe; Julie Bell; Esther Oliva; Robert H Young; Cynthia Cohen; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

View more
  4 in total

1.  Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.

Authors:  Tanan Bejrananda; Kanet Kanjanapradit; Jirakrit Saetang; Surasak Sangkhathat
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

2.  Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.

Authors:  Cosima Völkel; Noémi De Wispelaere; Sören Weidemann; Natalia Gorbokon; Maximilian Lennartz; Andreas M Luebke; Claudia Hube-Magg; Martina Kluth; Christoph Fraune; Katharina Möller; Christian Bernreuther; Patrick Lebok; Till S Clauditz; Frank Jacobsen; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer H Krech; David Dum; Till Krech; Andreas H Marx; Ronald Simon; Eike Burandt; Anne Menz
Journal:  Virchows Arch       Date:  2021-09-24       Impact factor: 4.064

Review 3.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

4.  Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.

Authors:  Atif Ali Hashmi; Zubaida Fida Hussain; Muhammad Irfan; Muhammad Muzzammil Edhi; Sarah Kanwal; Naveen Faridi; Amir Khan
Journal:  BMC Res Notes       Date:  2018-03-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.